Savara Inc

SVRA Nasdaq SEC CIK 1160308
Follow Savara Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$43M −45.4% vs same quarter last year
EPS, diluted −$0.17 −21.4% vs same quarter last year
Operating cash flow −$42.5M −88.5% vs same quarter last year
Operating income −$43.5M −43.9% vs same quarter last year
Net income by quarter
−$29M
−$26.6M
−$30.4M
−$29.6M
−$32.2M
−$37.3M
−$40.2M
−$43M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$118.8M
FY24-−$95.9M
FY23-−$54.7M
FY22-−$38.2M
FY21-−$43M
FY20$257K−$49.6M
FY19$0−$78.2M
FY18-−$61.5M
FY17$0−$29.8M
FY16$400K−$10.9M
FY15$54K−$9M
FY14$0−$28.7M
FY13$0−$21.5M
FY12$0−$15.6M
FY11-−$13.3M
MarginsShare of revenue
  • Operating margin
  • Net margin
−20000%−15000%−10000%−5000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21--
FY20−19182.9%−19305.4%
FY19--
FY18--
FY17--
FY16−2737%−2730.8%
FY15−10968.5%−16664.8%
FY14--
FY13--
FY12--
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$101.1M
FY24−$89.1M
FY23−$51.4M
FY22−$34.6M
FY21−$40.1M
FY20−$39.9M
FY19−$45.3M
FY18−$39.4M
FY17−$28.7M
FY16−$8.4M
FY15−$4.9M
FY14−$24.8M
FY13−$17.8M
FY12−$14.2M
FY11−$13.9M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Savara
  • Healthcare median
−20000%−15000%−10000%−5000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearSavaraHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.9%
FY20−19305.4%−62.2%
FY19-−46.3%
FY18-−49.6%
FY17-−45.9%
FY16−2730.8%−36%
FY15−16664.8%−38.4%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%